Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue

被引：0
|
作者：
Andrew G. Chambers
David C. Chain
Steve M. Sweet
Zifeng Song
Philip L. Martin
Matthew J. Ellis
Claire Rooney
Yeoun Jin Kim
机构：
[1] AstraZeneca,Early Oncology
[2] AstraZeneca,Early Oncology
来源：
Clinical Proteomics | 2023年 / 20卷
关键词：
Mass spectrometry; Targeted proteomics; FFPE; Translational medicine; Target engagement;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] DEVELOPMENT OF COMBINATION THERAPIES OF KRASG12C INHIBITOR ADAGRASIB IN PRECLINICAL MODELS OF BRAIN METASTASIS
    Torrini, Consuelo
    Migliarese, Christian
    Summers, Elizabeth
    Demir, Fatma Turna
    Ijad, Nazanin
    Nayyar, Naema
    Yamazawa, Erika
    De Sauvage, Magali
    Brastianos, Priscilla
    Wakimoto, Hiroaki
    NEURO-ONCOLOGY, 2023, 25
  • [32] Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
    Li, Hui-yu
    Qi, Wei-liang
    Wang, Yu-xiang
    Meng, Ling-hua
    GENES & DISEASES, 2023, 10 (02) : 403 - 414
  • [33] A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation.
    Price, Timothy
    Grewal, Jaspreet
    Abed, Afaf
    Moore, Melissa
    Yeh, Yu-Min
    Gadgeel, Shirish
    Richardson, Gary
    Underhill, Craig
    Ganju, Vinod
    Lee, Keun-Wook
    Huh, Seok Jae
    Kim, Sang-We
    Yang, Chih-Hsin
    Chen, Yuh-Min
    Xiang, Ziyong
    Shi, Zhe
    Wang, Yaolin
    Zhang, Ling
    Millward, Michael
    CANCER RESEARCH, 2022, 82 (12)
  • [34] Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
    Chen, Qi-An
    Lin, Wei-Hao
    Zhou, Xiao-Xiang
    Cao, Zheng
    Feng, Xiao-Li
    Gao, Yi-Bo
    He, Jie
    PHARMACOLOGICAL RESEARCH, 2024, 200
  • [35] The discovery and preclinical characterization of the potent covalent KRASG12C inhibitor UCT-001024
    Rose, Tristin E.
    O'Boyle, Brendan M.
    Hilf, Justin A.
    Baker-Tripp, Emma L.
    Feng, Zhengao
    Yang, Kevin
    Bartberger, Michael D.
    Loson, Oliver C.
    O'Brien, Neil A.
    McDermott, Martina S.
    Kamranpour, Naeimeh
    Jia, Weiping
    Luo, Tong
    Ayala, Raul
    Glasby, John
    Stoltz, Brian M.
    Slamon, Dennis J.
    CANCER RESEARCH, 2023, 83 (07)
  • [36] Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor
    Zhang, Liang
    Griffin, Daniel J.
    Beaver, Matthew G.
    Blue, Laura E.
    Borths, Christopher J.
    Brown, Derek B.
    Caille, Seb
    Chen, Ying
    Cherney, Alan H.
    Cochran, Brian M.
    Colyer, John T.
    Corbett, Michael T.
    Correll, Tiffany L.
    Crockett, Richard D.
    Dai, Xi-Jie
    Dornan, Peter K.
    Farrell, Robert P.
    Hedley, Simon J.
    Hsieh, Hsiao-Wu
    Huang, Liang
    Huggins, Seth
    Liu, Min
    Lovette, Michael A.
    Quasdorf, Kyle
    Powazinik, William
    Reifman, Jonathan
    Robinson, Jo Anna
    Sangodkar, Rahul P.
    Sharma, Sonika
    Kumar, Srividya Sharvan
    Smith, Austin G.
    St-Pierre, Gabrielle
    Tedrow, Jason S.
    Thiel, Oliver R.
    Truong, Jonathan V.
    Walker, Shawn D.
    Wei, Carolyn S.
    Wilsily, Ashraf
    Xie, Yong
    Yang, Ning
    Parsons, Andrew T.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2022, 26 (11) : 3115 - 3125
  • [37] Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C
    Patel, Snahel
    Bhhatarai, Barun
    Calses, Philamer
    Erlanson, Daniel
    Everley, Robert
    Fong, Susan
    Gerken, Phil
    Hermann, Johannes C.
    Le, Tiep
    Liu, Li-kai
    McMahon, Evan
    Neve, Richard M.
    Phan, Tony
    Roberts, Allison
    Shanafelt, Mikayla
    Siemsgluess, Sophie
    Staunton, Jocelyn
    Wang, Yan
    Wang, Weiru
    Williams, Monika
    Webster, Kevin R.
    CANCER RESEARCH, 2023, 83 (07)
  • [38] Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors
    Gu, Shaoulai
    Li, Qiang
    Li, Chao
    Wang, Qixin
    Fang, Douglas D.
    Wang, Shaomeng
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2022, 82 (12)
  • [39] Inhibition of ULK and KRASG12C control tumor growth in preclinical models of lung cancer
    Ghazi, Phaedra
    O'Toole, Kayla
    Boggaram, Sanjana
    Scherzer, Michael
    Bogdan, Madhumita
    Smith, Bryan
    Flynn, Dan
    Kinsey, Conan
    McMahon, Martin
    CANCER RESEARCH, 2024, 84 (06)
  • [40] The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRASG12C inhibitor adagrasib in KRASG12C non-small cell lung carcinoma
    Patel, Hetika V.
    Smith, Alison
    Chan, Stacia
    Kessler, Linda
    Burrows, Francis
    Malik, Shivani
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
12345